Abstract
Purpose
Although guidelines suggest the routine use of mupirocin or gentamicin at the exit site of PD catheter, our PD unit has been using chlorhexidine gluconate 0.5 % as exit-site care protocol. The aim of this study was to ascertain whether mupirocin application is superior to the traditionally applied chlorhexidine—regarding prevention of exit-site infections and peritonitis in our unit.
Methods
Stable incident and prevalent patients of our unit were randomized to apply mupirocin or chlorhexidine at exit site. The study started on July 1, 2010, and continued till December 2014. End point was the first episode of exit-site infection or peritonitis.
Results
Sixty-two patients (mean age 58.5 ± 14.6 years) were randomized. At the end of follow-up, there were 33 patients on mupirocin treatment and 29 on chlorhexidine. The two groups had no differences in age, sex, PD vintage or PD mode. The only difference between the two groups was the percentage of patients with diabetes, 28 % in chlorhexidine group versus 10 % in mupirocin group. Mean time of follow-up was 28.46 ± 16.37 months. Twenty-four episodes of infections (peritonitis and exit site) were recorded. Time to first infection episode was 32 months in mupirocin group (95 % CI 21.4–42.5) versus 29 months (95 % CI 8.6–49.4) in chlorhexidine group. The Kaplan–Meier survival analysis revealed no difference in the infections between the two protocols (log-rank test, p = 0.477).
Conclusions
Mupirocin is not superior in preventing infections comparing with chlorhexidine in this cohort of patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Piraino B, Bernardini J, Brown E, Figueiredo A, Johnson DW, Lye WC, Price V, Ramalakshmi S, Szeto CC (2011) ISPD position statement on reducing the risks of peritoneal dialysis-related infections. Perit Dial Int 31(6):614–630. doi:10.3747/pdi.2011.00057
Xu G, Tu W, Xu C (2010) Mupirocin for preventing exit-site infection and peritonitis in patients undergoing peritoneal dialysis. Nephrol Dial Transplant 25(2):587–592. doi:10.1093/ndt/gfp411
Chu KH, Choy WY, Cheung CC, Fung KS, Tang HL, Lee W, Cheuk A, Yim KF, Chan WH, Tong KL (2008) A prospective study of the efficacy of local application of gentamicin versus mupirocin in the prevention of peritoneal dialysis catheter-related infections. Perit Dial Int 28(5):505–508
Patel PR, Yi SH, Booth S, Bren V, Downham G, Hess S, Kelley K, Lincoln M, Morrissette K, Lindberg C, Jernigan JA, Kallen AJ (2013) Bloodstream infection rates in outpatient hemodialysis facilities participating in a collaborative prevention effort: a quality improvement report. Am J Kidney Dis 62(2):322–330. doi:10.1053/j.ajkd.2013.03.011
Rosenblum A, Wang W, Ball LK, Latham C, Maddux FW, Lacson E Jr (2014) Hemodialysis catheter care strategies: a cluster-randomized quality improvement initiative. Am J Kidney Dis 63(2):259–267. doi:10.1053/j.ajkd.2013.08.019
Shelton DM (1991) A comparison of the effects of two antiseptic agents on Staphylococcus epidermidis colony forming units at the peritoneal dialysis catheter exit site. Adv Perit Dial 7:120–124
Perez-Fontan M, Rosales M, Rodriguez-Carmona A, Falcon TG, Valdes F (2002) Mupirocin resistance after long-term use for Staphylococcus aureus colonization in patients undergoing chronic peritoneal dialysis. Am J Kidney Dis 39(2):337–341
Piraino B (2012) Today’s approaches to prevent peritonitis. Contrib Nephrol 178:246–250. doi:10.1159/000337886
Bernardini J, Bender F, Florio T, Sloand J, Palmmontalbano L, Fried L, Piraino B (2005) Randomized, double-blind trial of antibiotic exit site cream for prevention of exit site infection in peritoneal dialysis patients. J Am Soc Nephrol JASN 16(2):539–545. doi:10.1681/ASN.2004090773
Nessim SJ, Jassal SV (2012) Gentamicin-resistant infections in peritoneal dialysis patients using topical gentamicin exit-site prophylaxis: a report of two cases. Perit Dial Int 32(3):339–341. doi:10.3747/pdi.2011.00224
Johnson DW, Badve SV, Pascoe EM, Beller E, Cass A, Clark C, de Zoysa J, Isbel NM, McTaggart S, Morrish AT, Playford EG, Scaria A, Snelling P, Vergara LA, Hawley CM, Group HSC (2014) Antibacterial honey for the prevention of peritoneal-dialysis-related infections (HONEYPOT): a randomised trial. Lancet Infect Dis 14(1):23–30. doi:10.1016/S1473-3099(13)70258-5
Patel PR, Kallen AJ (2014) Bloodstream infection prevention in ESRD: forging a pathway for success. Am J Kidney Dis 63(2):180–182. doi:10.1053/j.ajkd.2013.11.003
Camins BC, Richmond AM, Dyer KL, Zimmerman HN, Coyne DW, Rothstein M, Fraser VJ (2010) A crossover intervention trial evaluating the efficacy of a chlorhexidine-impregnated sponge in reducing catheter-related bloodstream infections among patients undergoing hemodialysis. Infect Control Hosp Epidemiol 31(11):1118–1123. doi:10.1086/657075
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All authors declare that they have no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Additional information
An erratum to this article can be found at http://dx.doi.org/10.1007/s11255-016-1445-2.
Rights and permissions
About this article
Cite this article
Olga, B., Fotis, Z., Margarita, I. et al. Chlorhexidine for routine PD catheter exit-site care. Int Urol Nephrol 48, 1543–1546 (2016). https://doi.org/10.1007/s11255-016-1370-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11255-016-1370-4